

February 19, 2022

Mah Sing Healthcare Sdn Bhd Sazalinda Musa Senior RA Executive Wisma Mah Sing, Penthouse Suite 1, 163 Jalan Sungai Besi Kuala Lumpur, Kuala Lumpur 57100 Malaysia

Re: K214110

Trade/Device Name: Nitrile Powder Free Blue Patient Examination Gloves Non-Sterile, Tested For Use With Chemotherapy Drugs
Regulation Number: 21 CFR 880.6250
Regulation Name: Non-Powdered Patient Examination Glove
Regulatory Class: Class I, reserved
Product Code: LZA, LZC
Dated: December 17, 2021
Received: December 29, 2021

Dear Sazalinda Musa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <u>https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems</u>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</u>) and CDRH Learn (<u>https://www.fda.gov/training-and-continuing-education/cdrh-learn</u>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</u>) for more information or contact DICE by email (<u>DICE@fda.hhs.gov</u>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Clarence W. Murray, III, PhD Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number *(if known)* K214110

**Device Name** 

Nitrile Powder Free Blue Patient Examination Gloves Non-Sterile, Tested for use with Chemotherapy Drugs

Indications for Use (Describe)

A patient examination glove is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.

These gloves were tested for use with Chemotherapy Drugs as per ASTM D6978-05 (2019), Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs:

Chemotherapy Drugs Permeation The following chemicals have been tested with these gloves.

Test Chemotherapy Drugs Concentration Breakthrough Detection Time in minutes \*Carmustine 3.3mg/ml 24.8 Cisplatin 1 mg/ml >240 Cyclophosphamide 20 mg/ml >240 Dacarbazine 10 mg/ml >240 Doxorubicin, HCl 2 mg/ml >240 Etoposide 20 mg/ml >240 Fluorouracil 50 mg/ml >240 Methotrexate 25 mg/ml >240 Mitomycin C 0.5 mg/ml >240 Oxaliplatin 5 mg/ml >240 Paclitaxel 6 mg/ml >240 \*Thiotepa 10 mg/ml 38.4 Vincristine 1 mg/ml >240

Warning- Not for use with Carmustine and Thiotepa.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

✓ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov* 

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



### Premarket Notification [510(k)] No: K214110

1.0 Device Name	Nitrile Powder Free Blue Patient Examination Gloves, Non-Sterile,
	Tested For Use With Chemotherapy Drugs.
2.0 Submitter name / Contact details	Mah Sing Healthcare Sdn. Bhd Wisma Mah Sing, Penthouse Suite 1, 163 Jalan Sungai Besi, Kuala Lumpur 57100 MALAYSIA
	Contact Person Details: Sazalinda Musa (Ms) E-mail: sazalinda.m@mshealthcare.com Tel: +60-3-3396 2288, Extn: 2282 Fax: +60-3-3396 2299
3.0 Summary Preparation Date	December 17, 2021
4.0 Device Name & Classification	Trade Name: Nitrile Powder Free Blue Patient Examination Gloves, Non-sterile, Tested For Use With Chemotherapy Drugs.
	Common Name: Nitrile Powder Free Patient Examination Glove
	Classification Name: Patient Examination Gloves Specialty (code LZC), Polymer Patient Examination Gloves (code LZA).
	Device Classification: I
	Regulation Number: 21 CFR 880.6250
	Panel: General Hospital
	Product Code: LZC, LZA
5.0 Identification of The Legally Marketed Device	Predicate Device Name: Dermagrip Powder Free Blue Nitrile Patient Examination Gloves, Non-sterile, Tested For Us With Chemotherapy Drugs
	Predicate 510(K) Number: K161422
	Manufacture's Name: WRP Asia Pacific Sdn Bhd.

DrivingInnovation. Protecting Lives.

Lot 6478, Lorong Sungai Puloh / KU6, Kawasan Industri Sungai Puloh, 42100 Klang, Selangor. MALAYSIA T 603 3396 2288 F 603 3396 2299 mshealthcare.com



	Nitrile Powder Free Blue Patient Examination Gloves Non-sterile, Tested For Use With Chemotherapy Drugs meets all the requirements of ASTM standards D6319-19, D6978-05 (2019) and FDA 21 CFR 880.6250.				
	Nitrile Powder Free Blue Patient Examination Gloves Non-sterile, Tested For Use With Chemotherapy Drugs are Class I patient examination gloves bear the product code Nitrile – LZA (21CFR880.6250).				
	The gloves are made from ac Inner surface of gloves under smooth surface that assists th any lubricant such as powder in color and are powder free. T on right hand or left hand, sin sizes (S, M, L and XL). Th strength meet ASTM D 6319-	goes surface treat the user in donning on the glove surf The gloves are amb gle use disposable e physical proper	ment process to produce a g the gloves without using ace. These gloves are blue bidextrous i.e., can be worn e devices that come in four		
7.0 Indications for Use	A patient examination glove is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.				
	These gloves were tested for use with Chemotherapy Drugs as per ASTM D6978-05 (2019), Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs:				
	Chemotherapy Drugs Permea The following chemicals have				
	The following chemicals have	e been tested with	these gloves.		
	Test Chemotherapy Drugs	Concentration	these gloves. Breakthrough Detection Time in minutes		
	_	1	Breakthrough Detection		
	Test Chemotherapy Drugs *Carmustine Cisplatin	Concentration 3.3mg/ml 1 mg/ml	Breakthrough Detection Time in minutes 24.8 >240		
	Test Chemotherapy Drugs *Carmustine Cisplatin Cyclophosphamide	Concentration 3.3mg/ml 1 mg/ml 20 mg/ml	Breakthrough Detection Time in minutes 24.8 >240 >240		
	Test Chemotherapy Drugs *Carmustine Cisplatin Cyclophosphamide Dacarbazine	Concentration3.3mg/ml1 mg/ml20 mg/ml10 mg/ml	Breakthrough Detection Time in minutes 24.8 >240 >240 >240 >240		
	Test Chemotherapy Drugs *Carmustine Cisplatin Cyclophosphamide Dacarbazine Doxorubicin, HCl	Concentration3.3mg/ml1 mg/ml20 mg/ml10 mg/ml2 mg/ml	Breakthrough Detection Time in minutes 24.8 >240 >240 >240 >240 >240		
	Test Chemotherapy Drugs *Carmustine Cisplatin Cyclophosphamide Dacarbazine Doxorubicin, HCl Etoposide	Concentration           3.3mg/ml           1 mg/ml           20 mg/ml           10 mg/ml           2 mg/ml           20 mg/ml	Breakthrough Detection Time in minutes 24.8 >240 >240 >240 >240 >240 >240 >240		
	Test Chemotherapy Drugs *Carmustine Cisplatin Cyclophosphamide Dacarbazine Doxorubicin, HCl Etoposide Fluorouracil	Concentration           3.3mg/ml           1 mg/ml           20 mg/ml           10 mg/ml           2 mg/ml           20 mg/ml           50 mg/ml	Breakthrough Detection Time in minutes 24.8 >240 >240 >240 >240 >240 >240 >240 >240		
	Test Chemotherapy Drugs *Carmustine Cisplatin Cyclophosphamide Dacarbazine Doxorubicin, HCl Etoposide Fluorouracil Methotrexate	Concentration           3.3mg/ml           1 mg/ml           20 mg/ml           10 mg/ml           2 mg/ml           20 mg/ml	Breakthrough Detection Time in minutes 24.8 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240		
	Test Chemotherapy Drugs *Carmustine Cisplatin Cyclophosphamide Dacarbazine Doxorubicin, HCl Etoposide Fluorouracil Methotrexate Mitomycin C	Concentration           3.3mg/ml           1 mg/ml           20 mg/ml           10 mg/ml           2 mg/ml           20 mg/ml           20 mg/ml           20 mg/ml           0.5 mg/ml	Breakthrough Detection Time in minutes 24.8 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240		
	Test Chemotherapy Drugs *Carmustine Cisplatin Cyclophosphamide Dacarbazine Doxorubicin, HCl Etoposide Fluorouracil Methotrexate Mitomycin C Oxaliplatin	Concentration           3.3mg/ml           1 mg/ml           20 mg/ml           10 mg/ml           2 mg/ml           20 mg/ml           50 mg/ml           50 mg/ml           55 mg/ml           55 mg/ml	Breakthrough Detection Time in minutes 24.8 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240		
	Test Chemotherapy Drugs *Carmustine Cisplatin Cyclophosphamide Dacarbazine Doxorubicin, HCl Etoposide Fluorouracil Methotrexate Mitomycin C	Concentration           3.3mg/ml           1 mg/ml           20 mg/ml           10 mg/ml           2 mg/ml           20 mg/ml           20 mg/ml           20 mg/ml           0.5 mg/ml	Breakthrough Detection Time in minutes 24.8 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240 >240		

(2) Thiotepa - 38.4 minutes.

Kawasan Industri Sungai Puloh,

42100 Klang, Selangor.

MALAYSIA

MAH SING HEALTHCARE SDN BHD Lot 6478, Lorong Sungai Puloh / KU6, T 603 3396 2288 F 603 3396 2299 mshealthcare.com



 8.0 Summary of the Technological Characteristic of the Device
 Nitrile Powder Free Blue Patient Examination Gloves Non-sterile, Tested For Use With Chemotherapy Drugs meets all the requirements of ASTM standards D6319-19, D6978-05 (2019) and FDA 21 CFR 880.6250.
 Nitrile Powder Free Blue Patient Examination Gloves Non-sterile, Tested Standards D6319-19, D6978-05 (2019) and FDA 21 CFR 880.6250.

Nitrile Powder Free Blue Patient Examination Gloves Non-sterile, Tested For Use With Chemotherapy Drugs are Class I patient examination gloves bear the product code Nitrile – LZA (21CFR880.6250).

The gloves are made from acrylonitrile-butadiene copolymer dispersion. Inner surface of gloves undergoes surface treatment process to produce a smooth surface that assists the user in donning the gloves without using any lubricant such as powder on the glove surface. These gloves are blue in color and are powder free. The gloves are ambidextrous i.e., can be worn on right hand or left hand, single use disposable devices that come in four sizes (S, M, L and XL). The physical properties of glove, i.e., tensile strength meet ASTM D 6319-19.

Characteristics and Parameters	Standard	<b>Proposed Device</b>	Predicate device	Comparison Analysis
510(k) Number			K161422	-
Name of device		Nitrile Powder Free Blue Patient Examination Gloves, Non-Sterile	Powder Free Nitrile Examination Gloves Non- Sterile	Similar
Device Classification Name/Regulation Number	Patient Examination Glove, 21 CFR Part 880.6250	Patient Examination Glove, 21 CFR Part 880.6250	Patient Examination Glove, 21 CFR Part 880.6250	Similar
Product Code	-	LZA, LZC	LZA, LZC	Similar
Intended Use	-	A patient examination glove is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between patient and examiner	A patient examination glove is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.	Same intended use
Classification	-	Class 1	Class 1	Same Class
Raw Rubber Material	ASTM D 6319-19	Nitrile (Acrylonitrile- butadiene)	Nitrile (Acrylonitrile- butadiene)	Same synthetic rubber material
Design, Color and Surface Appearance	-	<ol> <li>Ambidextrous</li> <li>Blue</li> <li>Powder Free</li> <li>Finger Textured</li> </ol>	<ol> <li>Ambidextrous</li> <li>Blue</li> <li>Powder Free</li> <li>Finger Textured</li> </ol>	Same ambidextrous Design, same color, same features and Same textured area

# Table 1

MAH SING HEALTHCARE SDN BHD Lot 6478, Lorong Sungai Puloh / KU6,

Kawasan Industri Sungai Puloh,

T 603 3396 2288 F 603 3396 2299 mshealthcare.com

DrivingInnovation. Protecting Lives.

42100 Klang, Selangor. MALAYSIA



Characteristics and Parameters	Standard	Proposed Device	Predicate device	Comparison Analysis
Chemotherapy Drug Permeation Test	ASTM D6897-05			
Test Chemotherapy Drugs	Concentration	Minimum Breakthroug	h Detection Time (min)	
Fluorouracil	50 mg/ml	>240	>240	Similar
Etoposide	20 mg/ml	>240	>240	Similar
Cyclophosphamide	20 mg/ml	>240	>240	Similar
Fluorouracil	50 mg/ml	>240	>240	Similar
*Carmustine	3.3mg/ml	24.8	15.0	Similar Below 240 minutes permeation time, similar with predicate device
*Thiotepa	10 mg/ml	38.4	2.0	Similar Below 240 minutes permeation time, similar with predicate device
Paclitaxel	6 mg/ml	>240	>240	Similar
Doxorubicin, HCl	2 mg/ml	>240	>240	Similar
Dacarbazine	10 mg/ml	>240	>240	Similar
Cisplatin	1 mg/ml	>240	>240	Similar
Ifosfamide	50 mg/ml	Not tested	>240	Optional, Predicate device perform additional Chemotherapy drug test
Mitoxantrone	2.0 mg/ml	Not tested	>240	Optional, Predicate device perform additional Chemotherapy drug test
Vincristine	1 mg/ml	>240	>240	Similar
Methotrexate	25 mg/ml	>240	>240	Similar
Mitomycin C	0.5 mg/ml	>240	>240	Similar
Oxaliplatin	5 mg/ml	>240	Not tested	Optional, Subject device perform additional Chemotherapy drug test

#### MAH SING HEALTHCARE SDN BHD

Lot 6478, Lorong Sungai Puloh / KU6, Kawasan Industri Sungai Puloh, 42100 Klang, Selangor. MALAYSIA T 603 3396 2288 F 603 3396 2299 mshealthcare.com

Page 4 of 9



Characteristics and Parameters	Standard	Proposed Device	Predicate device	Comparison Analysis
Overall Length (Minimum 230mm)	ASTM D 6319-19	245 - 255 mm	Min. 240 mm	Similar
Width S: 75mm – 95mm M: 85mm – 105mm L: 100mm – 120mm XL:110mm – 130mm	ASTM D 6319-19	S: 83 - 85mm M: 93 - 96mm L: 105 - 109mm XL: 116 - 118mm	Not stated by predicate device	Similar, subject device meet requirements of ASTM D6319
Cuff Thickness (Minimum 0.05mm)	ASTM D 6319-19	0.05 - 0.06mm	0.06 - 0.08mm	Similar
Palm Thickness (Minimum 0.05mm)	ASTM D 6319-19	0.06 - 0.07 mm	0.07 - 0.10mm	Similar
Finger Thickness (Minimum 0.05mm)	ASTM D 6319-19	0.08 - 0.11mm	0.07 - 0.09mm	Similar
Tensile Strength (Before aging) Minimum 14 MPa	ASTM D 6319-19	Average: 21.96MPa	Meets	Similar
Tensile Strength (After accelerated aging) Minimum 14 MPa	ASTM D 6319-19	Average: 28.30MPa	Meets	Similar
Ultimate Elongation (before aging) Minimum 500%	ASTM D 6319-19	Average: 537%	Meets	Similar
Ultimate Elongation (after accelerated aging) Minimum 400%	ASTM D 6319-19	Average: 449%	Meets	Similar
Freedom of Holes Meet AQL 2.5 at G1	ASTM D 5151-19	Meet AQL 1.5 with G1	Passes	Similar
Residual powder test (Less than 2mg/glove)	ASTM D 6124-06	Average powder residue for each size. S: 0.32 mg /glove M: 0.28 mg /glove L: 0.32 mg /glove XL: 0.30 mg/glove	Average powder residue Meets	Similar
Animal Irritation Test	ISO 10993-10 Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization	Passed. Under the conditions of study, not an irritant	Passed Not a primary skin irritant under the conditions of the study	Similar
Dermal Sensitization	ISO 10993-10 Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization	Passed. Under the conditions of study, not a sensitizer	Passed Not a contact sensitizer under the conditions of the study	Similar
Acute Systemic Toxicity	ISO 10993-11 Biological evaluation of medical devices – Part 11: Tests for systemic toxicity	Not induce systemic toxicity	Predicate device has not performed test.	Subject devices meet requirements of ISO 10993-11

MAH SING HEALTHCARE SDN BHD Lot 6478, Lorong Sungai Puloh / KU6, Kawasan Industri Sungai Puloh, 42100 Klang, Selangor. MALAYSIA T 603 3396 2288 F 603 3396 2299 mshealthcare.com



Characteristics and Parameters	Standard	Proposed Device	Predicate device	Comparison Analysis
Expiration Date	ASTM D 7160-16 Standard Practice for Determination of Expiration Dating for Medical Gloves	3 years from date of manufactured	Predicate device has not stated.	-
Manufacturer	-	Mah Sing Healthcare Sdn. Bhd.	WRP Asia Pacific Sdn. Bhd.	-

# 9.0 Summary of Non-Clinical Testing

## Table 2 -Performance Testing

Non-Clinical Testing					
Test Method	Purpose	Acceptance Criteria			Result
ASTM D6124-06 (Reapproved 2017) Standard Test Method for Residual Powder on Medical Gloves.	To determine the residual powder in the gloves	Less than 2	2mg / glove	Size S Size M Size L Size XL	0.32mg /glove 0.28mg /glove 0.32mg /glove 0.30mg /glove
ASTM D5151-19 Standard Test Method for Detection of Holes in Medical Gloves.	To determine the holes in the gloves	Inspection level, G-I AQL 2.5 (In accordance with ASTM D6319-19)		Passed G-I	, AQL 1.5
ASTM D6319-19 Standard Specification for Nitrile Examination Gloves for Medical Application.	To determine the length of the gloves	Size S Size M Size L Size XL	220mm, min 230mm, min 230mm, min 230mm, min	Size S Size M Size L Size XL	250 - 255mm 250 - 255mm 245 - 252mm 245 - 252mm
ASTM D6319-19 Standard Specification for Nitrile Examination Gloves for Medical Application.	To determine the width of the gloves	Size S Size M Size L Size XL	$80 \pm 10$ mm 95 ± 10mm 110 ± 10mm 120 ± 10mm	Size S Size M Size L Size XL	S: 83 - 85mm M: 93 - 96mm L: 105 - 109mm XL: 116 - 118mm

MAH SING HEALTHCARE SDN BHD Lot 6478, Lorong Sungai Puloh / KU6, Kawasan Industri Sungai Puloh, 42100 Klang, Selangor. MALAYSIA T 603 3396 2288 F 603 3396 2299 mshealthcare.com



Non-Clinical Testing (Cont'd)					
Test Method	Purpose	Acceptance Criteria		Result	
ASTM D6319-19	To determine the	Measured	in single wall at c	uff edge area	L
Standard Specification for Nitrile Examination Gloves for Medical Application.	thickness of the gloves	Cuff	0.05mm, min	Size S Size M Size L Size XL	0.05 - 0.06mm 0.05 - 0.06mm 0.05 - 0.06mm 0.05 - 0.06mm
		Measured	in single wall at a	pproximate o	center of palm area
		Palm	0.05mm, min	Size S Size M Size L Size XL	0.06 - 0.07mm 0.06 - 0.06mm 0.06 - 0.07mm 0.06 - 0.07mm
		Measured	in single wall at 1	3±3mm fron	n the tip of middle finger
		Finger	0.05mm, min	Size S Size M Size L Size XL	0.08 - 0.09mm 0.09 - 0.10mm 0.10 - 0.11mm 0.10 - 0.11mm
ASTM D6319-19 Standard Specification for Nitrile Examination Gloves for Medical Application.	To determine the physical properties- Tensile strength	Before Ageing Tensile Strength 14Mpa, min for all sizes		Size S Size M Size L Size XL	21.94 MPa, average 22.08 MPa, average 21.76 MPa, average 22.05 MPa, average
		After Age Tensile Str 14Mpa, mi		Size S Size M Size L Size XL	29.53 MPa, average 29.12 MPa, average 24.90 MPa, average 29.63 MPa, average
	To determine the physical properties- Ultimate Elongation	Before Ag Ultimate E 500%, min		Size S Size M Size L Size XL	537%, average 550%, average 526%, average 536%, average
		After Age Ultimate E min for all	longation 400%,	Size S Size M Size L Size XL	452%, average 450%, average 436%, average 458%, average

DrivingInnovation. Protecting Lives.

MAH SING HEALTHCARE SDN BHD Lot 6478, Lorong Sungai Puloh / KU6, Kawasan Industri Sungai Puloh, 42100 Klang, Selangor. MALAYSIA T 603 3396 2288 F 603 3396 2299 mshealthcare.com



	Bio	compatibility Testing	
Test Method	Purpose	Acceptance Criteria	Result
ISO 10993-10 Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization (Animal Irritation Test)	To determine the potential of the material under test to produce dermal irritation in Rabbits	Under the condition of study not an irritant.	There was no observable irreversible alteration on the skin at the sites of contact with the test material. The Primary Irritation Index (PII) was "0". The test material was not corrosive, and the Primary Irritation Response Category is therefore "negligible", thereof met the requirement.
ISO 10993-10 Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization (Dermal Sensitization Assay Test)	To determine the skin sensitization potential of the material both in terms of induction and elicitation in Guinea pig	Under the condition of the study not a sensitizer.	There was no sensitization induced by the application of the test material on the albino guinea pigs under the condition of this test, thereof met the requirement.
ISO 10993-11 Biological evaluation of medical devices - Part 11: Tests for systemic toxicity (Acute Systemic Toxicity)	To provide information on health hazards likely to arise from a short-term exposure to the extracts of test material by intravenous and intraperitoneal injection in mice	Not induce systemic toxicity	Under the condition of this study, the single dose acute systemic toxicity of extracts from test material using both normal saline and sesame oil, shown non- toxic effects, thereof met the requirement.

Non-clinical tests were carried out to demonstrate product performance conformity with standards referenced.

The following bench tests were performed:

Non-clinical tests

- Residual Powder Content
- Physical Properties
- Physical Dimension
- Freedom from Holes

### **Biocompatibility Testing**

- Animal Irritation Test
- Dermal Sensitization Assay
- Acute Systemic Toxicity

The results from these performance evaluations demonstrated that the Nitrile Powder Free Blue Patient Examination Gloves, Non-Sterile, Tested For Use With Chemotherapy Drugs met the acceptance criteria defined in standards referenced.

MAH SING HEALTHCARE SDN BHD Lot 6478, Lorong Sungai Puloh / KU6, Kawasan Industri Sungai Puloh, 42100 Klang, Selangor. MALAYSIA T 603 3396 2288 F 603 3396 2299 mshealthcare.com



10.0 Summary of Clinic	al Testing: Clinical Testing is not needed for this dev	vice.
11.0 Conclusion	The conclusion drawn from the non-clinical test demo subject device is as safe, as effective, and performs as than the legally marketed predicate device K161422.	

DrivingInnovation. Protecting Lives.

MAH SING HEALTHCARE SDN BHD Lot 6478, Lorong Sungai Puloh / KU6, Kawasan Industri Sungai Puloh, 42100 Klang, Selangor. MALAYSIA T 603 3396 2288 F 603 3396 2299 mshealthcare.com